Long-term efforts have been devoted to develop tyrosine kinase inhibitors targeting the continuously activated ROS1 proteins resulted by chromosomal rearrangements, and crizotinib has received approval of the U.S. Food and Drug Administration (FDA) for ROS1-rearranged cancers (3). This evidence concerns the gene ROS1 and cancer.